← All trials
NCT01825811
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2012
- Primary completion
- Apr 1, 2014
- Completion date
- Jun 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- TissueGene, Inc.Lead sponsor
- Sungkyunkwan UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Inha UniversityOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Ewha Womans UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.